The inhibitory effect of heat treatment against epithelial-mesenchymal transition (EMT) in human pancreatic adenocarcinoma cell lines

Reiko Kimura-Tsuchiya, Takeshi Ishikawa, Satoshi Kokura, Katsura Mizushima, Satoko Adachi, Manabu Okajima, Tatsuo Matsuyama, Tetsuya Okayama, Naoyuki Sakamoto, Kazuhiro Katada, Kazuhiro Kamada, Kazuhiro Uchiyama, Osamu Handa, Tomohisa Takagi, Nobuaki Yagi, Yuji Naito and Yoshito Itoh

1Department of Molecular Gastroenterology and Hepatology and 2Department of Cancer Immune Cell Regulation, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kamigyoku, Kyoto 602-8566, Japan
3Kyoto Gakuen University, 1-1 Nanjiyo-Otani, Sogabe, Kameoka, Kyoto 621-8555, Japan

(Received 17 January, 2014; Accepted 5 February, 2014; Published online 13 May, 2014)

Epithelial-mesenchymal transition (EMT) plays a crucial role in cancer metastasis. In this study, we evaluated the effect of heat treatment on tumor growth factor-β1 (TGF-β1)-induced EMT in pancreatic cancer cells and tried to ascertain the mechanism related to any observed effects. Human pancreatic cancer cell lines (BxPC-3, PANC-1 and MIAPaCa-2) were stimulated by TGF-β1, and evaluated for morphological changes using immunofluorescence and EMT-related factors (i.e., E-cadherin, Vimentin, Snail or ZEB-1) using RT-PCR. To examine the effect of heat on EMT, the cancer cells were heat-treated at 43°C for 1 h then stimulated with TGF-β1. We then evaluated whether or not heat treatment changed the expression of EMT-related factors and cell migration and also whether Smad activation was inhibited in TGF-β1 signaling. After being treated with TGF-β1, pancreatic cancer cells resulted in EMT and cell migration was enhanced. Heat treatment inhibited TGF-β1-induced changes in morphology, inhibited the expression of EMT-related factors, and attenuated TGF-β1-induced migration in pancreatic cancer cells. Additionally, we observed that heat treatment blocked TGF-β1-induced phosphorylation of Smad2 in PANC-1 cells. Our results suggest that heat treatment can suppress TGF-β1-induced EMT and opens the possibility of a new therapeutic use of hyperthermia as a potential treatment for cancer metastasis.

Key Words: pancreatic cancer, epithelial-mesenchymal transition, heat treatment, hyperthermia, TGF-β1

Pancreatic cancer is the fifth most common cause of cancer-related death in Japan. Factors responsible for high mortality rates are late diagnosis due to the lack of early symptoms, extreme difficulty in resecting the tumor, extensive metastasis, and high resistance to treatment. (1) Unfortunately, there remains no effective therapy available for this aggressive tumor. Gemcitabine is the clinical standard for most chemotherapy regimens for pancreatic cancer; however patients generally have limited response to this therapy. To date, randomized trials of two regimens—gemcitabine plus erlotinib and a combination of 5-FU (5-fluorouracil), leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) have demonstrated significant prolongation of overall survival (OS). (2,3) However, gemcitabine plus erlotinib resulted in a statistically significant but relatively small improvement (0.33 months) in median OS (6.24 vs 5.91 months), (3) while the FOLFIRINOX regimen proved quite toxic. (4) To this end, more effective, better tolerated regimens are required to improve the outcome of patients with advanced pancreatic cancer.

Hyperthermia has been shown to increase the cytotoxic effects of some anti-cancer agents by facilitating increased drug penetration into tissues and causing thermal destruction of cancer cells. (5) Numerous phase II and phase III studies have shown that hyperthermia is feasible and effective in a variety of solid tumors especially if combined with chemotherapy or radiotherapy. (6–9) Moreover, we have previously demonstrated the safety and efficacy of a combined regional hyperthermia and gemcitabine treatment in patients with advanced pancreatic cancer. (9) In this phase II study, patients with locally advanced pancreatic cancer had a better outcome than those with metastatic pancreatic cancer (median OS, 17.7 vs 5.2 months, respectively). The results in patients with locally advanced, non-metastatic pancreatic cancer compare favorably with previous studies of 5-FU or gemcitabine with radiation, which reported a median OS of 8–10 months. (10–12) Since it has been proven that regional hyperthermia combined with gemcitabine improve the prognosis of patients with locally advanced pancreatic cancer, we hypothesized that epithelial-mesenchymal transition (EMT) inhibition may be the principal mechanism by which hyperthermia deters the progression of pancreatic cancer.

Recently, it has been purported that EMT is crucial to cancer invasion and metastasis. (13) The EMT phenotype is characterized by (1) the loss of cell-to-cell adhesion with the disintegration of tight, adherens, and gap junctions, and (2) a phenotypic change where cells shift from an “epithelial” morphology to an elongated fibroblast-like morphology which is associated with increased motility and tumor invasion. (14) The process of EMT involves the up-regulation of mesenchymal markers such as vimentin, N-cadherin and fibropectin, and the down-regulation of epithelial adhesion molecules such as E-cadherin and cytokeratins. (15,16) EMT is triggered by the interplay of extracellular signals (such as collagen) and many secreted soluble factors such as Wnt, transforming growth factor-β (TGF-β), fibroblast growth factor, epidermal growth factor, hepatocyte growth factor, and platelet-derived growth factors. Among these signaling pathways, the Wnt, TGF-β, Hedgehog, Notch, and nuclear factor-κB (NF-κB) signaling pathways are critical for EMT induction. (15,17) Coupled with its involvement in cancer metastasis, emerging lines of evidence also suggest that there is a molecular link between EMT phenotype and chemo-resistance or radio-
Cells were incubated at 37 °C in a humidified atmosphere containing 5% CO₂, 1640 supplemented with 10% fetal bovine serum (FBS), L-glutamine, and penicillin (100 U/ml)/streptomycin (100 μg/ml). MIAPaCa-2 cells were cultured in Dulbecco’s Modified Eagle Medium (DME) low glucose supplemented with 10% FBS, L-glutamine, and penicillin (100 U/ml)/streptomycin (2.5 μg/ml). Cells were incubated at 37 °C in a humidified atmosphere containing 5% CO₂.

Induction of EMT and heat treatment. EMT induction was undertaken using TGF-β1 (R&D Systems, Minneapolis, MN). PAN-1, MIAPaCa-2, and BxPC-3 cells were incubated in a serum-free medium supplemented with 10 ng/ml TGF-β1 in a humidified 5% CO₂ atmosphere at 37°C for 48 h. Before exposing cancer cells to TGF-β1, cells were incubated in a temperature-controlled CO₂ incubator at 43 °C for 60 min. After the cells were pretreated with heat, they were exposed to passive cooling in a temperature controlled CO₂ incubator at 37 °C before further examination.

Evaluation of cell migration using wound healing assay.

Wound-healing assay was performed as previously described with minor modifications. Briefly, the cells were seeded in 35-mm dishes and cultured until they reached confluence. The cells were then incubated with serum-free culture medium for 24 h, and scraped with a 10 μl extra-long micro-pipette tip, denuding a strip of the monolayer approximately 500 μm in diameter. Cultures were washed twice with PBS to remove cell debris and incubated with serum-free medium supplemented with 10% FBS, L-glutamine, and penicillin (100 U/ml)/streptomycin (2.5 μg/ml). After incubation, the cells were photographed with a digital camera, and the migrated area was measured using NIH Image (ver. 1.63) software. To ensure that the same wounds were compared, we used a permanent marker to make positioning marks at the bottom of the culture dishes. The migration area in the wound was calculated according to the following formula: cell free area at 0 h subtracted from the cell free area at 12-, 18-, and 24-h.

Immunocytochemistry. PAN-1, MIAPaCa-2, and BxPC-3 cells were incubated in 35-mm μ dishes (iBidi, Munich, Germany) were washed with PBS and fixed with 4% paraformaldehyde for 20 min at room temperature. Cells were then incubated with anti-E-cadherin (R&D Systems) and anti-vimentin (Santa Cruz Biotechnology, Santa Cruz, CA) for 2 h. Subsequently, cells were incubated with fluorescence-labeled secondary antibodies (Alexa Fluor 594, Life Technologies, Tokyo, Japan) for 1 h at room temperature and stained was observed using epi-illumination on a laser scanning confocal microscope (Olympus, Tokyo, Japan).

Reverse transcription-polymerase chain reaction (RT-PCR).

The expression levels of E-cadherin, Vimentin, Snail, and ZEB-1 mRNA were determined using real-time PCR. The samples used for mRNA isolation were removed from the pancreatic cancer cells (PANC-1, MIAPaCa-2 and BxPC-3). Total RNA was isolated using the acid guanidinium phenol chloroform method with Isogen (Nippon Gene Co. Ltd., Tokyo, Japan). The isolated RNA was stored at -80°C until use in real-time PCR. Subsequently, 1 μg of extracted RNA was reverse-transcribed into first-strand complementary DNA (cDNA) using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster, CA). Real-time PCR for E-cadherin, Vimentin, Snail, ZEB-1 and GAPDH was performed with the 7300 Real-Time PCR system (Applied Biosystems) using the RNA-binding dye SYBR Green to detect the PCR products. The primers had the following sequences: for E-cadherin, sense 5'-GTCAGTTCAAGCTCC-AGGCC-3' and antisense 5'-AAATCTACTCGCCAGCAAGAC-3'; for Vimentin, sense 5'-TCTAGAGGAGGAGTGGG-3' and antisense 5'-GGTCAGAGCTGCGAGAGGC-3'; for Snail, sense 5'-ACCACATGCGCGCTTCTT-3' and antisense 5'-GTCGTGAGGCTGCGAGAGGC-3'; for GAPDH 5'-ACCACACTGTCCTCAACGAG-3' and antisense 5'-CCATCAGCCACAGTTTCC-3'.

Western blotting. Cells were washed twice with ice-cold PBS. After removing the upper PBS, the cell pellets were lysed in Lysis Buffer (CellLyte M; Sigma-Aldrich Co., St. Louis, MO), treated with a cell scraper and stirred and incubated on ice for 15 min. The supernatants were centrifuged and stored at -80°C, and total proteins were mixed with an SDS sample buffer. The samples were then subjected to 10% SDS-PAGE and blotted onto a polyvinylidene fluoride membrane (Atto Corporation, Tokyo, Japan). The membrane was then incubated with 10% EzBlock (Atto Corporation) in TBS-T [10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% Tween-20 V/V] for 30 min at room temperature and washed with TBS-T three times. The membrane was incubated for 1 h at room temperature with anti-E-cadherin (R&D Systems), anti-phospho-Smad2 (UPSTATE, Lake Placid, NY) and anti-Smad2 (Cell Signaling Technology, Beverly, MA) in TBS-T (diluted 1:500). Following this the membrane was then incubated with the secondary anti-rabbit and mouse IgG antibodies (GE Healthcare, Tokyo, Japan) in TBS-T (diluted 1:1000) for 1 h at room temperature.

Effects of heat treatment on molecular marker of EMT. Immuno-fluorescence staining for E-cadherin (epithelial marker) was done on PANC-1, MIAPaCa-2, and BxPC-3 cells. The expression of E-cadherin was observed in only BxPC-3 cells, however, it was not observed even in the absence of TGF-β1 in the other two cell lines (i.e., PANC-1, MIAPaCa-2) (data not shown). After exposure to TGF-β1 for 48 h, E-cadherin expression of BxPC-3 cells was weaker, but it was reversed when pre-treated with heat (Fig. 2A). To further confirm our observation, we assessed the E-cadherin protein expression levels by Western blot (Fig. 2B).

Results

Heat treatment inhibits morphologic changes consistent with EMT in the presence of TGF-β1. After being treated with TGF-β1, the morphology in pancreatic cancer cells changed from a typical epithelium to a mesenchymal spindle shape. Heat treatment for 1 h prior to TGF-β1 exposure inhibited morphologic changes consistent with EMT. Especially in MIAPaCa-2 which is originally circular, the morphology was quite obvious (Fig. 1).

Effects of heat treatment on molecular marker of EMT. Immuno-fluorescence staining for E-cadherin (epithelial marker) was done on PANC-1, MIAPaCa-2, and BxPC-3 cells. The expression of E-cadherin was observed in only BxPC-3 cells, however, it was not observed even in the absence of TGF-β1 in the other two cell lines (i.e., PANC-1, MIAPaCa-2) (data not shown). After exposure to TGF-β1 for 48 h, E-cadherin expression of BxPC-3 cells was weaker, but it was reversed when pre-treated with heat (Fig. 2A). To further confirm our observation, we assessed the E-cadherin protein expression levels by Western blot (Fig. 2B). The expression of E-cadherin slightly decreased after exposure to TGF-β1, and post heat treatment its expression increased.
distinctly increased. As shown in Fig. 3A, in three pancreatic cancer cell lines that underwent EMT after being treated with TGF-β1, the expression of vimentin, which is one of the mesenchymal markers, was observed in cells that acquired a mesenchymal spindle-shape. Heat treatment reduced the expression of vimentin induced by TGF-β1 (Fig. 3A). We assessed the levels of vimentin and transcriptional suppressors of E-cadherin (i.e., Snail or ZEB-1) by quantitative RT-PCR. In BxPC-3 and MIAPaCa-2 cells, the expression of vimentin was significantly up-regulated by TGF-β1 treatment, however post heat treatment vimentin expression was blocked. In PANC-1 cells, vimentin expression showed a similar albeit insignificant tendency (Fig. 3B). In regards to the transcriptional suppressors of E-cadherin, the expression of Snail was up-regulated by TGF-β1 treatment in PANC-1 and MIAPaCa-2 cells; subsequently this up-regulation was significantly blocked by heat treatment in MIAPaCa-2 cells.

In PANC-1 cells, heat treatment tended to attenuate TGF-β1-induced Snail expression (Fig. 3B). In BxPC-3 cells, the expression of Snail did not change significantly after exposure to both TGF-β1 and heat treatment (data not shown); this lead us to take a look at ZEB-1 expression in BxPC-3 cells. We observed that ZEB-1 expression was up-regulated by TGF-β1 treatment in BxPC-3 cells, and this up-regulation was then significantly blocked by heat treatment (Fig. 3B).

**Heat treatment inhibits the phosphorylation of Smad2.**

To elucidate the mechanism by which heat treatment inhibits TGF-β1-induced EMT, the role of heat in regulating of Smad2 expression and phosphorylation, which is involved in the signaling pathway of TGF-β, was investigated in PANC-1 cells by Western blot. Exposure of cells to TGF-β1 resulted in the phosphorylation of Smad2 and heat treatment blocked the TGF-β1-induced phosphorylation of Smad2. Although exposure to TGF-β1

---

**Fig. 1.** Morphological changes after TGF-β1 and heat treatment in MIAPaCa-2 cells. Control: untreated cells. TGF-β1: Cells were treated with TGF-β1 (10 ng/ml) for 48 h. TGF-β1 + HT (heat treatment): Cells were heat-treated at 43°C for 1 h then stimulated with TGF-β1.

**Fig. 2.** Immunofluorescence staining and Western blot analysis of E-cadherin in BxPC-3 cells. After exposure to TGF-β1 (10 ng/ml) for 48 h, E-cadherin expression in BxPC-3 cells weakened, but it was reversed by 1 h of heat treatment. HT: heat treatment.
decreased Smad2, heat treatment did not affect total Smad2 levels in cells exposed to TGF-β1 (Fig. 4).

**Heat treatment suppresses migration potential of PANC-1 cells.** Next, using wound healing assays, we examined the effect of heat treatment on the migratory capability of PANC-1 cells. Twenty four hours after the induction of the scratch wound, cell migration into the wound was captured by microscope. Significant wound healing was seen after 24 h in cells treated with TGF-β1 compared to the control (absence of TGF-β1). Heat treatment inhibited wound closure in cells treated with TGF-β1 (Fig. 5), therefore it is safe to conclude that heat treatment can inhibit TGF-β1-induced migration in PANC-1 cells.

**Discussion**

Our focus in this study was to assess if heat treatment could inhibit EMT in pancreatic cancer cells and to further understand the mechanism involved. The results obtained so far indicate that heat treatment suppressed TGF-β1-induced EMT in pancreatic cancer cells. Moreover, our results strongly suggest that heat treatment inhibits TGF-β1-induced Smad2 activation in PANC-1 cells. This inhibition of Smad2 is considered to be one of the principal mechanisms for how heat treatment prevents TGF-β1-induced EMT. While there is one other research group that supports our result that heat treatment inhibits EMT in hepato-cellular carcinoma cells,\(^{23,24}\) the precise mechanisms of this inhibitory effect was not uncovered in their published reports and is still unknown. This is the first report to our knowledge that has described the mechanisms of the inhibitory effect of heat on EMT, involving the TGF-β/Smad signaling pathway.

Our results so far indicate that hyperthermia holds promise as a treatment for cancer metastasis. This is not surprising as several reports exist that suggest that hyperthermia has the potential to attenuate malignancy metastasis. Nagashima et al.\(^ {25}\) reported...
that hyperthermia, consisting of two 40-min sessions of radio-
frequency capacitive local heating at 43°C, significantly decreased
cervical lymph node metastasis from oral squamous cell carci-
nomas in hamsters. Moreover, clinical trial has demonstrated
that local hyperthermia could be effective at treating cervical
lymph node metastasis of oral cancer. Although the exact
mechanism of how hyperthermia inhibits metastases remains
unclear, the expressions of several genes related to cancer
metastasis such as membrane type 1-matrix metalloproteinase
(MT1-MMP), vascular endothelial growth factors (VEGFs), and
urokinase type plasminogen activator receptor (uPAR) were
shown to be down-regulated by heating. This supports the
notion that hyperthermia alters the metastatic capacities of tumors
by regulating metastasis related genes. While some progress is
being made in this regard, there are few reports about the effects
of hyperthermia on EMT, which is crucial in cancer invasion and
metastasis.

EMT is triggered either by environmental stresses such as
inflammation, reactive oxygen species, hypoxia and anoxia/
reperfusion or by a number of extracellular mediators, including
growth factors and cytokines, reactive oxygen species, and the
hypoxia-induced EMT in HepG2 hepatocellular carcinoma
cells. However, the mechanism by which hyperthermia attenuates
the expression of Snail using these two intracellular signaling
pathways was not made clear. What is known, is that the Smad
pathway, a major transducer of TGF-β signaling, is important
in TGF-β-induced EMT, and the hypoxia-induced factor-1 (HIF-1)
is the primary factor mediating hypoxia-induced EMT. In our
study, we have demonstrated that heat treatment attenuated
the phosphorylation of Smad2 induced by TGF-β1 in PANC-1 cells.
While TGF-β-induced phosphorylation of Smad2 in PANC-1 cells
was not so pronounced in this study, Horiguchi et al. have
recently reported that Ras signaling is important for the TGF-β-
induced Snail expression in PANC-1 cells. Thus, we hypothesize
that inhibition of the phosphorylation of Smad2 in TGF-β-
signaling is one of the mechanisms by which heat treatment
suppresses TGF-β1-induced EMT.

Heat stress elicits a wide spectrum of stress responses, including
an induction of heat shock proteins (HSPs), DNA and RNA
damage and reactive oxygen species production in mammalian
cells. Most HSPs play important roles as protein chaperones,
regulators of protein folding, supporters of the formation of
protein complexes and regulators of protein degradation. Recently
it has been revealed that several HSPs are involved in
EMT of renal tubular epithelial cells lung cells, and prostate cancer cells. While there is some agreement as to the
characteristics of HSPs, their effect on EMT is still controversial.
For example, HSP72 has been shown to inhibit TGF-β1-induced
EMT in renal epithelial cells by preventing TGF-β1-induced
phosphorylation and nuclear translocation of Smad and p-
Smad. In contrast, Noh et al. have demonstrated that
HSP90 inhibitor blocks TGF-β1-induced Smad phosphorylation
and induces the degradation of TGF-β type II receptor (TβRII),
thereby preventing TGF-β-stimulation from inducing EMT.
HSP27 is considered to be a component of several pathways,
including the IL-6/STAT3 pathway, known to induce EMT, in
prostate cancer. Additionally, the inhibition of HSP27 blocks
EMT features by promoting Snail degradation in lung cells.
In each study the observed effects of HSPs on EMT was different
and this may have resulted in part, not only from different kind
of HSPs addressed in the studies, but also from the different
types of cells that were used. Since heat can strongly induce
HSP72, it is possible that heat-induced HSP72 is involved in
blocking TGF-β1-induced Smad phosphorylation in the present
study. However, hyperthermia can induce not only a multitude of
HSPs but also various cellular responses. We have shown that
hyperthermia inhibits the activation of NF-κB, which can regulate
EMT-inducing transcription factors, in pancreatic cancer cells.
Several molecular mechanisms might underlie the inhibitory
effect of hyperthermia on EMT. However additional study is
required to clarify the precise mechanisms underlying the inhibi-
tory effects of hyperthermia on EMT.

In conclusion, this study has demonstrated for the first time
that hyperthermia inhibits TGF-β1-induced EMT by blocking
Smad2 phosphorylation in pancreatic cancer cells. EMT is more
than a feature of metastatic cells; it is a characteristic of cancer
stem cells and is associated with treatment resistance. Our
previous studies have shown the potential of hyperthermia
for overcoming gemcitabine resistance in pancreatic cancer. These
results combined with the results presented in this study strongly
suggest that hyperthermia could improve the prognosis of pancreatic cancer by suppressing cell metastasis.

Fig. 5. Migration assay of PANC-1 cells exposed to TGF-β1 with or without heat treatment. Twenty four hours after wound scratch, cell migration into the wound was captured by microscope. Cell migration was quantified in eight experiments: each line represents the ratio of time 0. *p<0.05, ***p<0.001. HT: heat treatment.
Acknowledgments

This study was partially supported by Grant-in-Aid for Scientific Research (No. 23590891) from the Japanese Ministry of Education, Culture, Sports, Science and Technology.

References

1. Dorado J, Lonardo E, Miranda-Lorenzo I, Heeschen C. Pancreatic cancer stem cells: new insights and perspectives. J Gastroenterol 2011; 46: 966–973.
2. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960–1966.
3. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
4. Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Lancet Oncol 2011; 12: 8–9.
5. Engelhardt R. Hyperthermia and drugs. Recent Results Cancer Res 1987; 104: 136–203.
6. Ishikawa T, Kokura S, Sakamoto N, et al. Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. Int J Hyperthermia 2012; 28: 597–604.
7. Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia 2001; 17: 1–18.
8. Wust P, Hildebrandt B, Sreenivasu G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002; 3: 487–497.
9. Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010; 11: 516–520.
10. Philip PA, Mooney M, Jaffe D, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 2009; 27: 5660–5669.
11. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Temporero MA. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 2003; 54: 107–116.
12. Ishii H, Okada S, Tokuyue K, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997; 79: 1516–1520.
13. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420–1428.
14. Hugo H, Ackland ML, Blick T, et al. Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression. J Cell Physiol 2007; 213: 374–383.
15. Min C, Eddy SF, Sherr DH, Sonenshein GE. NF-kappAB and epithelial to mesenchymal transition of cancer. J Cell Biochem 2008; 104: 733–744.
16. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3’ kinase/akt pathways. Oncogene 2005; 24: 7434–7443.
17. Wu Y, Zhou BP. New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin 2008; 40: 643–650.
18. Hiscox S, Jiang WG, Obermeier K, et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Canc 2006; 118: 290–301.
19. Wang Z, Li Y, Kong D, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009; 69: 2400–2407.
20. Ponti D, Zaffaroni N, Capelli C, Daidone MG. Breast cancer stem cells: an overview. Eur J Cancer 2006; 42: 1219–1224.
21. Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820–5828.
22. Uchiyama K, Naito Y, Tagaki T, et al. Carbon monoxide enhance colonic epithelial restitution via FGFR5 derived from colonic myofibroblasts. Biochem Biophys Res Commun 2010; 391: 1122–1126.
23. Yuan GJ, Li QW, Shan SL, Wang WM, Jiang S, Xu XM. Hyperthermia inhibits hypoxia-induced epithelial-mesenchymal transition in HepG2 hepatocellular carcinoma cells. World J Gastroenterol 2012; 18: 4781–4786.
24. Xu XM, Yuan GJ, Li QW, Shan SL, Jiang S. Hyperthermia inhibits transforming growth factor beta-induced epithelial-mesenchymal transition (EMT) in HepG2 hepatocellular carcinoma cells. Hepatogastroenterology 2012; 59: 2059–2063.
25. Nagashima K, Takagi R, Hoshina H. Effect of local hyperthermia on metastases in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2002; 31: 84–89.
26. Tohni H, Hayashi Y, Mitsudo K, Shigetomi T, Ueda M, Ishigaki T. Prognostic evaluation of preoperative thermochemotherapy for N(3) cervical lymph node metastases of oral cancer. Oncology 2002; 62: 234–240.
27. Sawaji Y, Sato T, Seiki M, Ito A. Heat shock-mediated transient increase in intracellular 3’,5’-cyclic AMP results in tumor specific suppression of membrane type 1-matrix metalloproteinase production and prolactin in A activation. Clin Exp Metastasis 2000; 18: 131–138.
28. Sawaji Y, Sato T, Takeuchi A, Hirata M, Ito A. Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro. Br J Cancer 2002; 86: 1597–1603.
29. Liang X, Zhou H, Liu X, et al. Effect of local hyperthermia on lymphangiogenic factors VEGF-C and -D in a nude mouse xenograft model of tongue squamous cell carcinoma. Oral Oncol 2010; 46: 111–115.
30. Fukao H, Ikeda M, Ichikawa T, et al. Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines. Clin Chim Acta 2000; 296: 17–33.
31. Okajima K, Kokura S, Ishikawa T, et al. Anoxia/reoxygenation induces epithelial-mesenchymal transition in human colon cancer cell lines. Oncol Rep 2013; 29: 2311–2317.
32. Sánchez-Tilló E, Liu Y, de Barrios O, et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci 2012; 69: 3429–3456.
33. Derycke R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577–584.
34. Horiguchi K, Shiraikhara T, Nakano A, Imamura T, Miyazono K, Saitoh K. Role of Ras signaling in the induction of snail by transforming growth factor-beta. J Biol Chem 2009; 284: 245–253.
35. Lindquist S, Craig EA. The heat-shock proteins. Annu Rev Genet 1988; 22: 61–677.
36. Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996; 381: 571–579.
37. Mao H, Li Z, Zhou Y, et al. HSP27 attenuates renal tubular cell apoptosis and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 2008; 295: F202–F214.
38. Zhou Y, Mao H, Li S, et al. HSP27 inhibits Smad3 activation and nuclear translocation in renal epithelial-mesenchymal transition. J Am Soc Nephrol 2010; 21: 598–609.
39. Noh H, Kim HJ, Yu MR, et al. Heat shock protein 90 inhibitor attenuates renal fibrosis through degradation of transforming growth factor-beta type II receptor. Lab Invest 2012; 92: 1583–1596.
40. Wettstein G, Bellaye PS, Kolb M, et al. Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation. FASEB J 2013; 27: 1549–1560.
41. Shiota M, Bishop JL, Nip KM, et al. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res 2013; 73: 3109–3119.
42. Adachi S, Kokura S, Okayama T, et al. Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines. Int J Hyperthermia 2009; 25: 210–219.
43. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871–890.

Conflict of Interest

No potential conflicts of interest were disclosed.

©2014 JCBN